Schaeffers Research·19h ago
Dow Futures Chart Over 400 Points Higher After Weak Jobs DataStock futures are moving notably higher as investors digest nonfarm payrolls and cooling yields
Moderna's transition from pandemic-driven demand to a seasonal commercial market has resulted in a severe revenue contraction, with 2026Q2 revenue of $145M down 85% from 2024Q3's $1.9B. The company's fixed-cost manufacturing footprint and persistent R&D spendi...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has collapsed from $1.9B in 2024Q3 to $145M in 2026Q2, with gross margin deteriorating to 35.9% and net losses of -$782M in the latest quarter.
Moderna is expected to launch over ten products by 2035, with a focus on respiratory vaccines and immuno-oncology, driving a Revenue CAGR of over +15% from 2026-2035.
Moderna specializes in mRNA therapeutics, leveraging its proprietary technology platform to develop innovative medicines, including vaccines and oncology treatments.
Moderna is making progress in its personalized cancer vaccine program, including late-stage data and collaborations with Merck, positioning it as a leader in immuno-oncology.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 31, 2026 | -$1.97+3.0% vs -$2.03 | $145M+40.9% vs $103M |
Q2 2026 May 1, 2026 | -$3.40+23.6% vs -$4.45 | $389M+64.6% vs $236M |
Q1 2026 Feb 13, 2026 | -$2.11+16.9% vs -$2.54 | $678M+6.7% vs $635M |
Q4 2025 Nov 6, 2025 | -$0.51+72.7% vs -$1.87 | $1.0B+10.3% vs $921M |
Stock futures are moving notably higher as investors digest nonfarm payrolls and cooling yields
Nike (NKE) faces persistent headwinds, with Q1 sales down 4% and China revenue plunging 22% year-over-year. Moderna (MRNA) will join the Nasdaq-100 replacing Warner Bros Discovery (WBD).
Moderna stock (NASDAQ: MRNA) rose more than 2% in early premarket trading on Friday after Nasdaq said the biotech company will join the Nasdaq-100 next week, creating new demand from index-tracking funds. The move follows a spectacular 2026 rally that has pushed Moderna more than 500% higher and transformed it from a post-pandemic recovery story into an oncology bet.
Nike slumps after the retailer misses analysts' first-quarter earnings target and issues downbeat full-year guidance.
Benchmark MRNA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Moderna, Inc. (MRNA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $190.01 | $75.39B | -26.17 | -39.23% | -145.16% | -28.87% | — | |
| $96.90 | $24.34B | -19.09 | 0.2% | -64.02% | -9.13% | — | |
| $10.46 | $1.72B | 4.12 | 64.69% | -59.87% | — | — | |
| $4.66 | $1.05B | 6.47 | 895.54% | 37.93% | 33.02% | — | |
| $27.80 | $158.44B | 20.44 | -1.65% | 6.81% | 4.87% | — | |
| $256.03 | $616.32B | 23.21 | 6.05% | 21.58% | 25.75% | — |
Moderna, Inc. (MRNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Moderna, Inc. (MRNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 31, 2026·SEC
Jul 8, 2026·SEC
May 11, 2026·SEC
Get notified when MRNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Moderna, Inc. (MRNA) stock FAQ — growth, dividends, profitability & financials explained
Moderna, Inc. (MRNA) reported $2.23B in revenue for fiscal year 2025. This represents a 1955% increase from $108.4M in 2016.
Moderna, Inc. (MRNA) saw revenue decline by 39.2% over the past year.
Moderna, Inc. (MRNA) reported a net loss of $3.15B for fiscal year 2025.
Moderna, Inc. (MRNA) has a return on equity (ROE) of -28.9%. Negative ROE indicates the company is unprofitable.
Moderna, Inc. (MRNA) had negative free cash flow of $1.22B in fiscal year 2025, likely due to heavy capital investments.
